×
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
NASDAQ:BVXV

BiondVax Pharmaceuticals Stock Forecast, Price & News

$1.16
-0.05 (-4.13%)
(As of 06/24/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.16
$1.25
50-Day Range
$1.16
$1.65
52-Week Range
$1.00
$4.19
Volume
58,249 shs
Average Volume
753,404 shs
Market Capitalization
$13.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00
30 days | 90 days | 365 days | Advanced Chart

Receive BVXV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BiondVax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

BVXV Stock Forecast (MarketRank)

Overall MarketRank

1.53 out of 5 stars

Medical Sector

1014th out of 1,418 stocks

Biological Products, Except Diagnostic Industry

154th out of 216 stocks

Analyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
BiondVax Pharmaceuticals logo

About BiondVax Pharmaceuticals (NASDAQ:BVXV)

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.

BVXV Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BVXV
Employees
15
Year Founded
N/A

Company Calendar

Last Earnings
6/01/2022
Today
6/24/2022
Next Earnings (Estimated)
8/25/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$7.00
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+503.4%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
1 Analysts

Profitability

Net Income
$-12.85 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.66 per share

Miscellaneous

Free Float
10,669,000
Market Cap
$13.17 million
Optionable
Not Optionable
Beta
2.51














BiondVax Pharmaceuticals Frequently Asked Questions

Should I buy or sell BiondVax Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BiondVax Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BiondVax Pharmaceuticals stock.
View analyst ratings for BiondVax Pharmaceuticals
or view top-rated stocks.

What is BiondVax Pharmaceuticals' stock price forecast for 2022?

1 brokers have issued 1 year price objectives for BiondVax Pharmaceuticals' shares. Their BVXV stock forecasts range from $7.00 to $7.00. On average, they expect BiondVax Pharmaceuticals' stock price to reach $7.00 in the next year. This suggests a possible upside of 503.4% from the stock's current price.
View analysts' price targets for BiondVax Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has BiondVax Pharmaceuticals' stock price performed in 2022?

BiondVax Pharmaceuticals' stock was trading at $2.35 on January 1st, 2022. Since then, BVXV stock has decreased by 50.6% and is now trading at $1.16.
View the best growth stocks for 2022 here
.

Are investors shorting BiondVax Pharmaceuticals?

BiondVax Pharmaceuticals saw a decrease in short interest during the month of May. As of May 31st, there was short interest totaling 52,100 shares, a decrease of 15.4% from the May 15th total of 61,600 shares. Based on an average daily volume of 1,130,000 shares, the days-to-cover ratio is presently 0.0 days.
View BiondVax Pharmaceuticals' Short Interest
.

When is BiondVax Pharmaceuticals' next earnings date?

BiondVax Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 25th 2022.
View our earnings forecast for BiondVax Pharmaceuticals
.

How were BiondVax Pharmaceuticals' earnings last quarter?

BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) posted its quarterly earnings results on Wednesday, June, 1st. The company reported ($0.20) EPS for the quarter.
View BiondVax Pharmaceuticals' earnings history
.

Who are BiondVax Pharmaceuticals' key executives?

BiondVax Pharmaceuticals' management team includes the following people:
  • Mr. Amir Reichman M.B.A., M.Sc., CEO & Director (Age 46)
  • Mr. Uri Ben-Or CPA, CPA, M.B.A., MBA, Chief Financial Officer (Age 52)
  • Mr. Elad Mark B.Sc., Eng., M.B.A., Chief Operating Officer (Age 40)
  • Dr. Tamar Ben-Yedidia Ph.D., Chief Scientist (Age 58)
  • Mr. Joshua E. Phillipson B.Sc., M.B.A., Director of Bus. Devel. & Investor Relations
  • Ms. Moran Ahdout Fruchter L.L.B., Chief of Staff
  • Ms. Dalit Weinstein Fischer, Head of Technical R&D

What other stocks do shareholders of BiondVax Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BiondVax Pharmaceuticals investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pluristem Therapeutics (PSTI), Exelixis (EXEL), NVIDIA (NVDA), Teva Pharmaceutical Industries (TEVA), Adaptimmune Therapeutics (ADAP), AVEO Pharmaceuticals (AVEO), Anavex Life Sciences (AVXL) and Alibaba Group (BABA).

When did BiondVax Pharmaceuticals IPO?

(BVXV) raised $10 million in an IPO on Tuesday, May 12th 2015. The company issued 1,400,000 shares at a price of $7.32 per share. Aegis Capital Corp served as the underwriter for the IPO.

What is BiondVax Pharmaceuticals' stock symbol?

BiondVax Pharmaceuticals trades on the NASDAQ under the ticker symbol "BVXV."

How do I buy shares of BiondVax Pharmaceuticals?

Shares of BVXV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BiondVax Pharmaceuticals' stock price today?

One share of BVXV stock can currently be purchased for approximately $1.16.

How much money does BiondVax Pharmaceuticals make?

BiondVax Pharmaceuticals (NASDAQ:BVXV) has a market capitalization of $13.17 million. The company earns $-12.85 million in net income (profit) each year or ($0.77) on an earnings per share basis.

How many employees does BiondVax Pharmaceuticals have?

BiondVax Pharmaceuticals employs 15 workers across the globe.

How can I contact BiondVax Pharmaceuticals?

BiondVax Pharmaceuticals' mailing address is Jerusalem BioPark 2nd floor Hadassah Ein Kerem Campus, Jerusalem L3, 74036. The official website for BiondVax Pharmaceuticals is www.biondvax.com. The company can be reached via phone at 9723029302529, via email at [email protected], or via fax at 972-8930-2531.

This page (NASDAQ:BVXV) was last updated on 6/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.